MedTrace Logo

A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty

NCT07710430 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-07-29

No results posted yet for this study

Summary

A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty

Conditions

  • Central Precocious Puberty

Interventions

DRUG

Leuprorelin

Leuprorelin will be administered every 4 weeks.

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2029-08-30
Completion
2030-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07710430 on ClinicalTrials.gov